Vbi Vaccines Stock Buy Hold or Sell Recommendation
| VBIV Stock | USD 0.63 0.02 3.28% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding VBI Vaccines is 'Strong Sell'. Macroaxis provides VBI Vaccines buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding VBIV positions. The advice algorithm takes into account all of VBI Vaccines' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting VBI Vaccines' buy or sell advice are summarized below:
Real Value 1.46 | Target Price 4 | Hype Value 0.64 | Market Value 0.63 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell VBI Vaccines given historical horizon and risk tolerance towards VBI Vaccines. When Macroaxis issues a 'buy' or 'sell' recommendation for VBI Vaccines, the advice is generated through an automated system that utilizes algorithms and statistical models.
VBI |
Execute VBI Vaccines Buy or Sell Advice
The VBI recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on VBI Vaccines. Macroaxis does not own or have any residual interests in VBI Vaccines or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute VBI Vaccines' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
VBI Vaccines Trading Alerts and Improvement Suggestions
| VBI Vaccines had very high historical volatility over the last 90 days | |
| VBI Vaccines has some characteristics of a very speculative penny stock | |
| VBI Vaccines has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 8.68 M. Net Loss for the year was (92.84 M) with loss before overhead, payroll, taxes, and interest of (10.19 M). | |
| VBI Vaccines currently holds about 82.41 M in cash with (60.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.32. | |
| VBI Vaccines has a frail financial position based on the latest SEC disclosures | |
| Latest headline from investorplace.com: VBIV Stock Earnings VBI Vaccines Beats EPS, Misses Revenue for Q4 2023 |
VBI Vaccines Returns Distribution Density
The distribution of VBI Vaccines' historical returns is an attempt to chart the uncertainty of VBI Vaccines' future price movements. The chart of the probability distribution of VBI Vaccines daily returns describes the distribution of returns around its average expected value. We use VBI Vaccines price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of VBI Vaccines returns is essential to provide solid investment advice for VBI Vaccines.
| Mean Return | 0.30 | Value At Risk | -10.67 | Potential Upside | 7.14 | Standard Deviation | 6.64 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of VBI Vaccines historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
VBI Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as VBI Vaccines is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading VBI Vaccines backward and forwards among themselves. VBI Vaccines' institutional investor refers to the entity that pools money to purchase VBI Vaccines' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Alpine Partners Vi, Llc | 2023-12-31 | 25 K | Two Sigma Securities, Llc | 2023-12-31 | 24.6 K | Millennium Management Llc | 2023-12-31 | 22 K | Warberg Asset Management Llc | 2023-12-31 | 15 K | Captrust Financial Advisors | 2023-12-31 | 12.3 K | Steward Partners Investment Advisory, Llc | 2023-12-31 | 3.1 K | Royal Bank Of Canada | 2023-12-31 | 1.4 K | Newbridge Financial Services Group, Inc. | 2023-12-31 | 1.2 K | Wetzel Investment Advisors Inc | 2023-12-31 | 1000 | Perceptive Advisors Llc | 2023-12-31 | 1.4 M | Alyeska Investment Group, L.p. | 2023-09-30 | 696.7 K |
VBI Vaccines Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (15.1M) | 49.6M | 27.9M | (59.1M) | (38.9M) | (37.0M) | |
| Free Cash Flow | (52.4M) | (48.1M) | (41.9M) | (78.0M) | (61.8M) | (58.7M) | |
| Other Non Cash Items | 15K | 386K | 1.9M | 29.2M | 23.3M | 24.5M | |
| Capital Expenditures | 3.7M | 1M | 2.0M | 4.3M | 867K | 1.3M | |
| Net Income | (54.8M) | (46.2M) | (69.8M) | (113.3M) | (92.8M) | (88.2M) | |
| End Period Cash Flow | 44.2M | 93.8M | 121.7M | 62.6M | 23.7M | 26.8M | |
| Depreciation | 1.2M | 1.7M | 1.8M | 2.1M | 2.0M | 2.1M | |
| Change To Inventory | (385K) | (1.9M) | (513K) | (5.7M) | 1.7M | 1.8M | |
| Change To Netincome | 10.5M | 6.3M | 9.8M | 38.5M | 44.3M | 46.5M | |
| Change Receivables | (136K) | 130K | 69K | (87K) | (78.3K) | (74.4K) |
VBI Vaccines Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to VBI Vaccines or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that VBI Vaccines' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a VBI stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.26 | |
β | Beta against NYSE Composite | 0.42 | |
σ | Overall volatility | 6.77 | |
Ir | Information ratio | 0.03 |
VBI Vaccines Volatility Alert
VBI Vaccines is displaying above-average volatility over the selected time horizon. VBI Vaccines is a potential penny stock. Although VBI Vaccines may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in VBI Vaccines. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on VBI instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.VBI Vaccines Fundamentals Vs Peers
Comparing VBI Vaccines' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze VBI Vaccines' direct or indirect competition across all of the common fundamentals between VBI Vaccines and the related equities. This way, we can detect undervalued stocks with similar characteristics as VBI Vaccines or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of VBI Vaccines' fundamental indicators could also be used in its relative valuation, which is a method of valuing VBI Vaccines by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare VBI Vaccines to competition |
| Fundamentals | VBI Vaccines | Peer Average |
| Return On Equity | -2.2 | -0.31 |
| Return On Asset | -0.29 | -0.14 |
| Operating Margin | (0.98) % | (5.51) % |
| Current Valuation | 31 M | 16.62 B |
| Shares Outstanding | 28.43 M | 571.82 M |
| Shares Owned By Insiders | 7.69 % | 10.09 % |
| Shares Owned By Institutions | 11.84 % | 39.21 % |
| Number Of Shares Shorted | 289.12 K | 4.71 M |
| Price To Earning | (3.79) X | 28.72 X |
| Price To Book | 0.82 X | 9.51 X |
| Price To Sales | 2.02 X | 11.42 X |
| Revenue | 8.68 M | 9.43 B |
| Gross Profit | (10.19 M) | 27.38 B |
| EBITDA | (79.91 M) | 3.9 B |
| Net Income | (92.84 M) | 570.98 M |
| Cash And Equivalents | 82.41 M | 2.7 B |
| Cash Per Share | 0.32 X | 5.01 X |
| Total Debt | 53.04 M | 5.32 B |
| Debt To Equity | 0.32 % | 48.70 % |
| Current Ratio | 2.29 X | 2.16 X |
| Book Value Per Share | 0.85 X | 1.93 K |
| Cash Flow From Operations | (60.88 M) | 971.22 M |
| Short Ratio | 3.78 X | 4.00 X |
| Earnings Per Share | (9.79) X | 3.12 X |
| Target Price | 5.0 | |
| Number Of Employees | 190 | 18.84 K |
| Beta | 1.92 | -0.15 |
| Market Capitalization | 17.06 M | 19.03 B |
| Total Asset | 86.95 M | 29.47 B |
| Retained Earnings | (582.45 M) | 9.33 B |
| Working Capital | (39.51 M) | 1.48 B |
| Current Asset | 7.89 M | 9.34 B |
| Current Liabilities | 3.03 M | 7.9 B |
Note: Acquisition by Avi Mazaltov of 52500 shares of VBI Vaccines subject to Rule 16b-3 [view details]
VBI Vaccines Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as VBI . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 10063.32 | |||
| Daily Balance Of Power | 0.5 | |||
| Rate Of Daily Change | 1.03 | |||
| Day Median Price | 0.63 | |||
| Day Typical Price | 0.63 | |||
| Price Action Indicator | 0.01 | |||
| Period Momentum Indicator | 0.02 |
About VBI Vaccines Buy or Sell Advice
When is the right time to buy or sell VBI Vaccines? Buying financial instruments such as VBI Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Total Stockholder Equity | 143.9M | 64.2M | 7.5M | 7.2M | Total Assets | 210.3M | 155.1M | 87.0M | 73.5M |
Use Investing Ideas to Build Portfolios
In addition to having VBI Vaccines in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Blend Funds Thematic Idea Now
Small Blend Funds
Fund or Etfs that invest in stocks of small to mid-sized entities that have characteristics of both growth and value companies. The Small Blend Funds theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Blend Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out VBI Vaccines Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for VBI Stock analysis
When running VBI Vaccines' price analysis, check to measure VBI Vaccines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VBI Vaccines is operating at the current time. Most of VBI Vaccines' value examination focuses on studying past and present price action to predict the probability of VBI Vaccines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VBI Vaccines' price. Additionally, you may evaluate how the addition of VBI Vaccines to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is VBI Vaccines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VBI Vaccines. If investors know VBI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VBI Vaccines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.79) | Revenue Per Share 0.689 | Quarterly Revenue Growth 19.896 | Return On Assets (0.29) | Return On Equity (2.20) |
The market value of VBI Vaccines is measured differently than its book value, which is the value of VBI that is recorded on the company's balance sheet. Investors also form their own opinion of VBI Vaccines' value that differs from its market value or its book value, called intrinsic value, which is VBI Vaccines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VBI Vaccines' market value can be influenced by many factors that don't directly affect VBI Vaccines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VBI Vaccines' value and its price as these two are different measures arrived at by different means. Investors typically determine if VBI Vaccines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VBI Vaccines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.